Trial
NCT02469415
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
M.D. Anderson Cancer Center
Collaborators
CTI BioPharma
Condition
Leukemia
Intervention
Pacritinib
Why stopped
FDA Clinical Hold
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-10-16